Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spanlecortemlocel - Magenta Therapeutics

Drug Profile

Spanlecortemlocel - Magenta Therapeutics

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; MGTA-456

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Magenta Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Inborn error metabolic disorders

Most Recent Events

  • 13 Jan 2020 Magenta Therapeutics announces intention to discuss with the European Medicines Agency for development of Spanlecortemlocel in Europe in 2020
  • 13 Jan 2020 Magenta Therapeutics plans to complete enrolment in a phase II trial for Inborn error metabolic disorder in 2020
  • 04 Sep 2019 Spanlecortemlocel receives Regenerative Medicine Advance Therapy (RMAT) designation from the US FDA for Inborn error metabolic disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top